目的 探讨肝苏颗粒联合拉米夫定和阿德福韦酯治疗乙型肝炎肝硬化的临床疗效。方法 选取2014年5月-2015年5月在遂宁市中心医院接受治疗的乙型肝炎肝硬化患者82例，根据治疗方案的差别分为对照组（41例）和治疗组（41例）。对照组口服拉米夫定片，1片/次，1次/d；同时口服阿德福韦酯片，1片/次，1次/d。治疗组在对照组基础上口服肝苏颗粒，1袋/次，3次/d。两组患者均连续治疗12个月。观察两组的临床疗效，同时比较两组治疗前后谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）、白蛋白（ALB）、HBV-DNA转阴率、门静脉内径、脾脏厚度和脾静脉宽度的变化。结果 治疗后，对照组和治疗组的总有效率分别为75.61%、92.68%，两组比较差异有统计学意义（P<0.05）。治疗后，两组ALT、AST和TBIL均显著降低，ALB均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度均优于同期对照组，两组比较差异具有统计学意义（P<0.05）。同组治疗前及治疗后3、6个月HBV-DNA转阴率比较差异具有统计学意义（P<0.05）。治疗12个月，两组患者的门静脉内径、脾脏厚度和脾静脉宽度均显著降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗组这些观察指标的降低程度优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肝苏颗粒联合拉米夫定和阿德福韦酯治疗乙型肝炎肝硬化疗效确切，有利于患者肝功能改善，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Gansu Granules combined with lamivudine and adefovir dipivoxil in treatment of hepatitis B cirrhosis. Methods Patients (82 cases) with hepatitis B cirrhosis in Suining Central Hospital from May 2014 to May 2015 were divided into control (41 cases) and treatment (41 cases) groups according to different treatments. The patients in the control group were po administered with Lamivudine Tablets, 1 tablet/time, once daily, at the same time, they were po administered with Adefovir dipivoxil Tablets, 1 tablet/time, once daily. The patients in the treatment group were po administered with Gansu Granules on the basis of the control group, 1 bag/time, three times daily. The patients in two groups were treated for 12 months. After treatment, the efficacy was evaluated, the changes of ALT, AST, TBIL, ALB, negative conversion ratios of HBV-DNA, portal vein diameter, spleen thickness, and splenic vein width in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 75.61% and 92.68%, respectively, and there was difference between two groups (P<0.05). After treatment, ALT, AST, and TBIL in two groups were significantly decreased, ALB was significantly increased, and the difference was statistically significant in the same group (P<0.05). The improved degree of those observation indicators in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). The difference of the negative conversion ratios of HBV-DNA in the same group before treatment and treatment for 3 and 6 months was statistically significant (P<0.05). After treatment for 12 months, portal vein diameter, spleen thickness, and splenic vein width in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). The decrease degree of those observation indicators in the treatment group was better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Gansu Granules combined with lamivudine and adefovir dipivoxil has a definite clinical effect in treatment of hepatitis B cirrhosis, which is beneficial to improve the liver function of patients and has a certain clinical application value.